These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23928022)

  • 21. Prospective, non-comparative study of daptomycin for the treatment of superficial and deep incisional surgical site infections.
    Knapp AG; Kamepalli RK; Martone WJ; Yankelev S
    Surg Infect (Larchmt); 2011 Apr; 12(2):113-8. PubMed ID: 21348765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections.
    Timerman A; Brites C; Bicudo E; Grinbaum RS; Costa Filho R; Carrilho CD; Bichels A; Barreto T
    Braz J Infect Dis; 2013; 17(6):647-53. PubMed ID: 23916455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.
    Carugati M; Bayer AS; Miró JM; Park LP; Guimarães AC; Skoutelis A; Fortes CQ; Durante-Mangoni E; Hannan MM; Nacinovich F; Fernández-Hidalgo N; Grossi P; Tan RS; Holland T; Fowler VG; Corey RG; Chu VH;
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6213-22. PubMed ID: 24080644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.
    Britt NS; Potter EM; Patel N; Steed ME
    Clin Infect Dis; 2017 Mar; 64(5):605-613. PubMed ID: 28011602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.
    Gould IM; Miró JM; Rybak MJ
    Int J Antimicrob Agents; 2013 Sep; 42(3):202-10. PubMed ID: 23845504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with daptomycin in Europe: the first 2.5 years.
    Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Seaton RA; Loeffler J; Chaves RL
    J Antimicrob Chemother; 2011 Apr; 66(4):912-9. PubMed ID: 21393205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.
    Gonzalez-Ruiz A; Gargalianos-Kakolyris P; Timerman A; Sarma J; José González Ramallo V; Bouylout K; Trostmann U; Pathan R; Hamed K
    Adv Ther; 2015 Jun; 32(6):496-509. PubMed ID: 26108157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)].
    Lübbert C; Wilhelms D; Worlitzsch D; Ettrich TJ; Behl S; Seufferlein T
    Z Gastroenterol; 2012 Apr; 50(4):373-81. PubMed ID: 22430297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of daptomycin in the treatment of gram-positive infective endocarditis: a meta-analysis].
    Ge Y; Zhou J; Ma XJ
    Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(3):205-214. PubMed ID: 36649992
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.
    Sandoval N; Grau S; Sorlí L; Montero M; Esteve E; Horcajada JP
    Future Microbiol; 2015; 10(7):1145-54. PubMed ID: 26119704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper.
    Turnidge J; Kahlmeter G; Cantón R; MacGowan A; Giske CG;
    Clin Microbiol Infect; 2020 Aug; 26(8):1039-1043. PubMed ID: 32353412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.
    Rehm S; Campion M; Katz DE; Russo R; Boucher HW
    J Antimicrob Chemother; 2009 May; 63(5):1034-42. PubMed ID: 19264792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series.
    Ramaswamy DP; Amodio-Groton M; Scholand SJ
    BMC Urol; 2013 Jul; 13():33. PubMed ID: 23866912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. At least 8 mg/kg/d for the treatment of infective endocarditis.
    Flateau C
    Med Mal Infect; 2014 Jun; 44(6):286-7. PubMed ID: 25646548
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease.
    Vlashyn OO; Lorenz AM; Sobhanie MM; Smith JM; Bond M; Wardlow L
    J Clin Pharm Ther; 2021 Apr; 46(2):363-368. PubMed ID: 33016513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
    Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
    Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.